Model	Study name	Subgroup within study	Statistics with study removed					Risk ratio (95% CI) with study removed
			Point	Lower limit	Upper limit	Z-Value	p-Value	0.10 0.20 0.50 1.00 2.00 5.00 10.00
	Mease PJ et al., 2016	Ixekizumab	2.083	1.794	2.417	9.657	0.000	
	Mease PJ et al., 2015	Secukinumab	1.987	1.700	2.322	8.625	0.000	
	McInnes IB et al, 2015	Secukinumab	2.064	1.787	2.384	9.843	0.000	
	Mease PJ et al., 2014	Brodalumab	2.040	1.778	2.340	10.185	0.000	
	Ritchlin et al., 2014	Ustekinumab	2.036	1.770	2.342	9.957	0.000	
	McInnes IB et al., 2013	Ustekinumab	2.084	1.791	2.426	9.477	0.000	
	Gottileb AB et al., 2009	Ustekinumab	2.007	1.750	2.302	9.975	0.000	
Random			2.042	1.786	2.335	10.460	0.000	

Suppl. Fig 3. Sensitivity analysis - One study removed at a time and its effect on the primary end point effect estimates.